Akumin Inc

Akumin — Q1 2020 Earnings Presentation

11 slides from Akumin's earnings presentation, June 2020

  1. Slide 1: Q1 2020 Earnings Call

    Q1 2020 EARNINGS CALL TSX: AKU.U (US$) / AKU (C$)

  2. Slide 2: Forward-looking Information

    Forward-looking Information This report contains or incorporates by reference “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities laws. Forward-looking statements describe our future plans, strategies, Disclaimer expectations and objecti

  3. Slide 3: Agenda

    Agenda 1 1 2020 Financial Results Q Financial Summary Volume Revenue Adjusted EBITDA Balance Sheet 2 redit Agreement Amendment C 3 OVID-19 Status and Cost Containment C 3 PRESENTATION BY AKUMIN STRICTLY PRIVATE AND CONFIDENTIAL TSX: AKU.U (US$) / AKU (C$)

  4. Slide 4: Financial Summary

    Financial Summary Consolidated Financial Results (in thousands, except for EPS) Summary Q1 2020 Q1 2019 Q1 2020 results RVUs 1,525 1,066 affected by COVID-19 Revenue 71,262 47,551 in March 2020 EBITDA 20,311 12,044 Adjusted EBITDA 14,968 9,251 EPS – Diluted 0.02 0.03 Adjusted EPS – Diluted 0.03 0.05

  5. Slide 5: Volume: Relative Value Units (RVUs)

    Volume Relative Value Units (RVUs) (Values in thousands) Volumes impacted by COVID-19 during 1,583 1,525 March 2020 1,435 1 % same-center 1,163 decline in volume 1,066 (7% same-center growth excluding March 2020, which was impacted by COVID-19) 3% year-over-year 4 volume growth due to acquisitions Q

  6. Slide 6: Revenue

    Revenue Revenue (Values in USD thousands) Sequential decline $77,026 in revenue due to $68,874 $71,262 seasonality, COVID- related volume impact $53,985 and an incremental $47,551 0% year-over-year 5 bad debt provision to revenue growth account for potential elatively stable R COVID impacts pricing

  7. Slide 7: Adjusted EBITDA

    Adjusted Adjusted EBITDA (Values in USD thousands) EBITDA $20,231 Reduced EBITDA margin $18,039 due to lower revenue $14,968 $12,290 COVID-19 cost containment strategies $9,251 together with integration of acquired businesses expected to improve future margin profile Q1 2019 Q2 2019 Q3 2019 Q4 2019

  8. Slide 8: Balance Sheet

    Balance Sheet Day Sales DSO is 108 days (Q4 2019 – 98 days) Outstanding SO is 74 days excluding auto/attorney D As at March 31, 2020 (DSO) (1) payors (Q4 2019 – 66 days) Increase in DSO is mainly due to seasonally low collections in Q1 2020, impact of billing integration Ongoing focus on cost of acq

  9. Slide 9: Credit Agreement Amendment

    Credit Increased Revolver evolver capacity has been increased R from $50 million to $69 million Agreement Capacity raws beyond $50 million require D lender consents Amendment Currently $28.4 million drawn Adjusted covenant ovenant C our quarters of relief granted with F ratios provide greater Flexib

  10. Slide 10: COVID-19 Status and Cost Containment

    COVID-19 Current Status overnment “stay-at-home” and other measures G have largely been relaxed in our major markets Status and Cost aily average volume declined to a low point D of approximately 55% in mid-April 2020 but Containment rebounded to an estimated decline of 25% by late-May 2020(1) Clini

  11. Slide 11: Question & Answer

    QUESTION & ANSWER TSX: AKU.U (US$) / AKU (C$)

Akumin — Q1 2020 Earnings Presentation on 6ix